Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute of Rheumatology, NDORMS have identified a new target for treatment of particular inflammatory conditions, with the findings published this week in PNAS.

Blocking the protein interferon regulatory factor 5 (IRF5) would significantly reduce inflammation in certain chronic conditions, providing a more specific and effective treatment for patients, as well as fewer side effects from long-term use of current options.

Macrophages and neutrophils, two types of white blood cells, are the most abundant inflammatory cells in diseases driven by inflammation, like rheumatoid arthritis and acute lung injury. Each cell type can play opposing roles, with some macrophages increasing inflammation whilst other macrophages are helping to decrease it. Reducing the presence of these cells in inflamed areas, or switching their function to a ‘repair’ one, typically leads to profound therapeutic benefit.

IRF5 is very important in defining which role macrophages will play, as well as in neutrophil recruitment to affected areas, namely on acute lung injury, making it a great target for new therapies.

Kennedy researcher Miriam Weiss said: "These data highlight IRF5 as a very interesting drug target to treat inflammatory diseases such as rheumatoid arthritis. The next step will be to find ways to block this pathway, so we can move closer to an effective therapy."

You can read the full article here.

Image: neutrophils detected within the synovial capsule of inflamed knees. Left: control group; right: blocking IRF5.

Similar stories

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.